JB Chemicals & Pharmaceuticals Limited

rs,

ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company

60%

s multiple businesses 6 Brands among top 300 brands (IQVIA MAT Dec’22 data), contributing over 60% of domestic formulations revenues 40+ Regulated/semi-regulated markets of presence through dir

25%

Top 5 Global manufacturer of medicated/herbal lozenges representing a substantial opportunity 25% Growth in chronic therapies* in the domestic formulations business 2500+# Strong India field f

22%

cused segmentation 7 Multi-dosage formulation plants with key global approvals/ compliances **22% ROCE with consistent cash flow generation generating good returns * CAGR over FY20-FY22 (IQVIA

27.4%

4 Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) 27.4% 25.0% 24.5% 21.3% 18.6% 15.4% 1,413 1,643 1,775 2,043 2,424 2,387 139 194 272 449 3

25.0%

porate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) 27.4% 25.0% 24.5% 21.3% 18.6% 15.4% 1,413 1,643 1,775 2,043 2,424 2,387 139 194 272 449 386 322

24.5%

Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) 27.4% 25.0% 24.5% 21.3% 18.6% 15.4% 1,413 1,643 1,775 2,043 2,424 2,387 139 194 272 449 386 322 FY18

21.3%

t – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) 27.4% 25.0% 24.5% 21.3% 18.6% 15.4% 1,413 1,643 1,775 2,043 2,424 2,387 139 194 272 449 386 322 FY18 FY19

18.6%

ancial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) 27.4% 25.0% 24.5% 21.3% 18.6% 15.4% 1,413 1,643 1,775 2,043 2,424 2,387 139 194 272 449 386 322 FY18 FY19 FY20 F

15.4%

Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) 27.4% 25.0% 24.5% 21.3% 18.6% 15.4% 1,413 1,643 1,775 2,043 2,424 2,387 139 194 272 449 386 322 FY18 FY19 FY20 FY21 FY

15%

3 1,775 2,043 2,424 2,387 139 194 272 449 386 322 FY18 FY19 FY20 FY21 FY22 9M FY23 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% # 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) I

10%

775 2,043 2,424 2,387 139 194 272 449 386 322 FY18 FY19 FY20 FY21 FY22 9M FY23 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% # 22% 18% FY20 FY21 FY22 ROE (%) ROCE (%) Increa

“• Brands will be placed under priority promotion in an existing division • Around 60 people from high-volume/high-growth areas have been transferred to JB Enhances prescription productivity with cardiologists and consulting physicians Presenter’s Name: Presentation Date: DD/MM/YEAR”

Slide No.

3

Operating leverage

1

Slide No.

13 Razel to bring Synergy Benefits to JB Pharma Leverages the existing Go-To-Market model focussed for this segment and further strengthens our chronic portfolio With the acquisition of Razel, we are now present in the 3 most progressive cardiology segments • Statins : • Anti Hypertension : Cilacar and Nicardia • Heart Failure : Azmarda Razel

Operating leverage

• Brands will be placed under priority promotion in an existing division • Around 60 people from high-volume/high-growth areas have been transferred to JB Enhances prescription productivity with cardiologists and consulting physicians Presenter’s Name: Presentation Date: DD/MM/YEAR

Slide No.

14 JB Pharma Breaks into the Top 10 Companies in Cardiology Rank Company IQVIA MAT MAR'22 Ranks Company IQVIA MAT Dec'22 Grand Total SUN TORRENT PHARMA LUPIN LIMITED U S V CIPLA GLENMARK PHARMA MANKIND MACLEODS PHARMA INTAS PHARMA ABBOTT EMCURE ZYDUS CADILA JB PHARMA 1 2 3 4 5 6 7 8 9 10 11 12 13 22282 2308 1693 1537 1197 1171 1047 995 767 732 706 668 632 600 Grand Total SUN TORRENT PHARMA LUPIN LIMITED U S V CIPLA GLENMARK PHARMA MANKIND JB PHARMA INTAS PHARMA MACLEODS PHARMA ABBOTT DR REDDYS LABS ZYDUS CADILA 1 2 3 4 5 6 7 8 9 10 11 12 13 22973 2511 1799 1458 1373 1167 1138 1061 837 792 787 763 704 651 • Acquisition of Azmarda and Razel enables JB to gain 5 ranks in the Cardiology segment since March’22 Presenter’s Name: Presentation Date: DD/MM/YEAR

Slide No.

15 Revenue Analysis: International Business Q3 and 9M FY23 23% 386 315 Total International Business 26 % 896 1127 Total International Business 11% 267 241 92% 96 50 -4% 24 23 International Formulations CMO API Q3 FY22 Q3 FY23 13% 668 754 85% 306 165 6% 63 67 International Formulations CMO API 9M FY22 9M FY23 o International business continues its strong performance with revenue growing at 23% in Q3 FY23 and 26% in 9M FY23 • International formulations recorded highest ever quarterly sales • ROW and the US region recorded strong sales growth • Russia-CIS business showed improved revenue traction • South Africa public business witnessing competitive pressure o CMO business recorded 92% growth in Q3 FY23 to INR 96 crores • CMO accounted for 27% of International revenue for 9M FY23 as compared to 18% in 9M FY22 • New launches in specific markets showing good progress o Current geo-political and economic uncertainty continues to impact demand 16 Q3 and 9M FY23 Financial Performance (Consolid